Eva A. Pechatnikova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eva A. Pechatnikova has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Mezentsev
Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia, Russia
1 shared publication - Anna Gennadievna Soboleva
Research Institute of Molecular and Cellular Medicine, Peoples’ Friendship University of Russia (RUDN University), 6 Miklukho-Maklaya Street, Moscow 117198, Russia
1 shared publication - Elena V. Denisova
Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology; Center for Theoretical Problems of Physical and Chemical Pharmacology of Russian Academy of Sciences
1 shared publication - Eugenia Dvoryankova
Centre of Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences, 119334 Moscow, Russia
1 shared publication - Irina Markovna Korsunskaya
Center for Theoretical Problems of Physicochemical Pharmacology, Institution of Russian Academy of Sciences
1 shared publication - Vladimir Vasilievich Sobolev
Center for Theoretical Problems of Physical and Chemical Pharmacology of Russian Academy of Sciences
1 shared publication
Latest Publications
- Open Access
- 7 March 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (3) , 619
Proteomic Studies of Psoriasis
In this review paper, we discuss the contribution of proteomic studies to the discovery of disease-specific biomarkers to monitor the disease and evaluate available treatment options for psoriasis. Psoriasis is one of the most prevalent skin disorders driven by a Th17-specific immune response. Although potential patients have a genetic predisposition to psoriasis, the etiology of the disease remains unknown. During the last two decades, proteomics became deeply integrated with psoriatic research. The data obtained in proteomic studies facilitated the discovery of novel mechanisms and the verification of many experimental hypotheses of the disease pathogenesis. The detailed data analysis revealed multiple differentially expressed proteins and significant changes in proteome associated with the disease and drug efficacy. In this respect, there is a need for proteomic studies to characterize the role of the disease-specific biomarkers in the pathogenesis of psoriasis, develop clinical applications to choose the most efficient treatment options and monitor the therapeutic response.
- 7 March 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (3) , 619
Open AccessProteomic Studies of Psoriasis
In this review paper, we discuss the contribution of proteomic studies to the discovery of disease-specific biomarkers to monitor the disease and evaluate available treatment options for psoriasis. Psoriasis is one of the most prevalent skin disorders driven by a Th17-specific immune response. Although potential patients have a genetic predisposition to psoriasis, the etiology of the disease remains unknown. During the last two decades, proteomics became deeply integrated with psoriatic research. The data obtained in proteomic studies facilitated the discovery of novel mechanisms and the verification of many experimental hypotheses of the disease pathogenesis. The detailed data analysis revealed multiple differentially expressed proteins and significant changes in proteome associated with the disease and drug efficacy. In this respect, there is a need for proteomic studies to characterize the role of the disease-specific biomarkers in the pathogenesis of psoriasis, develop clinical applications to choose the most efficient treatment options and monitor the therapeutic response.